ArticleBMC ophthalmology2026
CoCl
Article in BMC ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCongenital aniridia is a rare disease, accompanied by aniridia associated keratopathy (AAK) in most cases. Oxidative stress and inflammation are involved in the progression of AAK. We aimed to evaluate antioxidative and inflammatory gene and protein expression in a small interfering RNA (siRNA) paired box 6 (PAX6) knockdown limbal epithelial cell (LEC) model of aniridia under cobalt chloride (CoCl
methodsTo mimic PAX6 haploinsufficiency in congenital aniridia, PAX6 expression was knocked down by 24-hour siRNA treatment in primary human LECs. Hypoxia-mimetic conditions were induced by 50 µM or 75 µM CoCl₂ for 48 h following siRNA transfection. Messenger RNA (mRNA) expression levels were analyzed by quantitative polymerase chain reaction (qPCR), while protein expression levels were assessed by enzyme-linked immunosorbent assay (ELISA) or western blotting.
resultsVascular endothelial growth factor A (VEGFA) protein levels were significantly increased in PAX6 knockdown LECs compared with control siRNA-treated cells (p = 0.007). In contrast, hypoxia-inducible factor 2-alpha (HIF-2α) and interleukin-6 (IL-6) mRNA levels (p = 0.031, p = 0.001), as well as interleukin-1 beta (IL-1β), IL-6, and interleukin-8 (IL-8) protein levels (p = 0.049, p < 0.001, p < 0.001, respectively), were significantly reduced in PAX6 knockdown cells compared with control siRNA-treated LECs. CoCl₂ treatment (50 and 75 µM) reduced hypoxia-inducible factor 1-alpha (HIF-1α) mRNA expression in both groups (p = 0.019 and p = 0.007; p < 0.001 and p = 0.046, respectively). In control cells, 75 µM CoCl₂ increased IL-1β and IL-8 mRNA expression (p = 0.022, p = 0.019) as well as IL-1β protein levels (p = 0.024), whereas IL-8 protein levels decreased at both concentrations (p = 0.002 and p < 0.001). No other analyzed genes showed significant expression changes in response to CoCl₂ treatment in either the control or PAX6 knockdown groups.
conclusionsOur study demonstrates altered expression of hypoxia-related (HIF-1α, HIF-2α) and inflammatory (IL-1β, IL-6, IL-8) genes in response to CoCl₂ treatment or PAX6 haploinsufficiency. Further investigation is needed to elucidate the effects of PAX6 knockdown and its interaction with inflammatory pathways. This research may contribute to better understanding of congenital aniridia.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.